Regenxbio
RGNX
188 hedge funds and large institutions have $1.15B invested in Regenxbio in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 64 increasing their positions, 59 reducing their positions, and 15 closing their positions.
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
9% more funds holding
Funds holding: 172 → 188 (+16)
8% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 59
5% more call options, than puts
Call options by funds: $3.6M | Put options by funds: $3.43M
1% less capital invested
Capital invested by funds: $1.16B → $1.15B (-$8.24M)
1.82% less ownership
Funds ownership: 83.09% → 81.26% (-1.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.4M |
| 2 |
Millennium Management
New York
|
+$5.27M |
| 3 |
WM
WS Management
Jacksonville,
Florida
|
+$5.25M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.86M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$14.9M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| 5 |
JP Morgan Chase
New York
|
-$7.78M |
RGNX Hedge Fund Activity: Q1 2022 in Review
188 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2022, worth a combined $1.15B — down 0.71% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RGNX positions and 15 closed out — a net gain of 17 holders — while 64 added to existing stakes and 59 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $14.4M. The largest seller was HHLR Advisors, exiting entirely with an estimated $14.9M sold.
- 188 institutional investors held Regenxbio (RGNX) as of Q1 2022, up from 172 in Q4 2021.
- Funds reported $1.15B of Regenxbio stock for Q1 2022, down 0.71% quarter-over-quarter.
- 32 funds opened new Regenxbio positions in Q1 2022 and 15 closed out, a net change of +17 holders.
- The largest Regenxbio buyer in Q1 2022 was Point72 Asset Management, an estimated $14.4M added.
- The largest Regenxbio seller in Q1 2022 was HHLR Advisors, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2022.